{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Wysdom Radio™","title":" C-TRACT Trial: Venous Stenting for Post-Thrombotic Syndrome","html":"","width":"100%","height":180,"duration":1131,"description":"This episode breaks down the landmark C-TRACT trial (NEJM 2026), a phase 3 randomized study testing whether iliac vein stenting plus enhanced antithrombotic therapy actually improves outcomes in patients with moderate-to-severe post-thrombotic syndrome (PTS). \nThe Clinical Question: Does restoring iliac venous outflow with stenting meaningfully improve symptoms and quality of life? \nResult: Endovascular therapy significantly improved symptom burden, with a meaningful reduction in VCSS severity and a striking 14.5-point improvement in quality-of-life scores. \nMechanical Win: Stent thrombosis was remarkably low at just 0.9%, reinforcing the importance of rigorous inflow assessment, mandatory IVUS, and aggressive stent sizing in chronic venous disease. \nTrade-Off: Bleeding complications were substantially higher in the intervention arm (11.6% vs. 3.6%), largely driven by prolonged dual antithrombotic therapy rather than the procedure itself. \nBottom Line: For carefully selected PTS patients with good inflow and significant iliac obstruction, iliac vein stenting can deliver meaningful symptom relief, but success depends heavily on patient selection, IVUS-guided technique, and thoughtful post-op management.\nTune in to learn which post-thrombotic patients actually benefit from venous stenting—and where the limits of the “open vein hypothesis” begin.","thumbnail_url":"https://img.transistorcdn.com/MTWsVlQNVWnqK7R-Z-jI7G_aa5KttFr_japy-P3mayc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81ODli/OTVlYjRiZjJlZGZi/ZDQxYmE2NDU2YmUx/Y2ZhMy5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}